DelveInsights launched a new report on Intrahepatic Cholangiocarcinoma (ICCA) Market Insights, Epidemiology and Market Forecast 2030.
DelveInsight’s ‘Intrahepatic Cholangiocarcinoma (ICCA) Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan
Intrahepatic cholangiocarcinoma (ICCA), a primary malignant neoplasm of the liver secondary to hepatocellular carcinoma, arises from the intrahepatic biliary epithelium (lining epithelia and peribiliary glands) and shows a variable cholangiocytic differentiation. The malignant tumor may arise from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural).
Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology Insights:
- In 2017, a total of 10,177 patients were affected with ICCA in the 7MM.
- The United States contributes the largest share with 3,639 incident cases in 2017, acquiring about 35.76% of the totals 7MM share. On the other hand, EU5 and Japan will account for 37.40% and 26.84% population share, respectively, by 2017.
- ICCA is slightly common in males as compared to females.
Request for sample pages of the report: https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market
Intrahepatic Cholangiocarcinoma (ICCA) Emerging Therapies:
1. Pemazyre (Pemigatinib): Incyte Corporation
2. Rozlytrek (Entrectinib): Roche
3. Melphalan/HDS: Delcath Systems
4. Derazantinib: Basilea Pharmaceutica
Intrahepatic Cholangiocarcinoma (ICCA) Market Outlook
Intrahepatic cholangiocarcinoma (ICCA) is the type of CCA that forms in the bile ducts inside the liver. The commonly available modalities for the treatment of ICCA include surgery and radiation therapies for curative intent and systemic therapies, including chemotherapy and chemoradiotherapy, for the surgery of ineligible patients.
Surgical resection is the mainstay for the treatment of ICCA. The main goal of the surgery is the hepatic resection with negative margins. Since this type of cancer occurs in the bile ducts inside the liver, surgery may include removing the section or wedge of the liver, and its extent depends on tumor size and location.
Locoregional therapies such as RFA, TACE, DEB-TACE or TACE drug-eluting microspheres, and TARE with yttrium-90 microspheres have shown to be effective in a retrospective analysis of patients with ICCA. Besides these, radiation therapy is also a locoregional treatment option for unresectable ICCA. Fewer patients with ICCA are also given ablation. Although all guidelines recommend radiofrequency ablation (RFA) as a standard treatment for patients with small, early-stage HCC not suitable for surgical therapies, in some cases, patients with ICCA are also treated with RFA.
Intrahepatic Cholangiocarcinoma (ICCA) Market Insights
- The Intrahepatic Cholangiocarcinoma (ICCA) market size in the 7MM was USD 99.78 million in 2017.
- Among the 7MM, the United States accounts for the highest market size of ICCA in comparison with EU5 and Japan.
Table of contents:
1 Key Insight
2 Executive Summary of Intrahepatic Cholangiocarcinoma (ICCA)
3 Intrahepatic Cholangiocarcinoma (ICCA) Market Overview at a Glance
4 Disease Background and Overview: Intrahepatic Cholangiocarcinoma (ICCA)
5 Case Reports
6 Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Intrahepatic Cholangiocarcinoma (ICCA) Treatment and Medical Practices
11 Unmet needs
12 Intrahepatic Cholangiocarcinoma (ICCA) Marketed Drugs
13 Intrahepatic Cholangiocarcinoma (ICCA) Emerging Drugs
14 Intrahepatic Cholangiocarcinoma (ICCA) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Intrahepatic Cholangiocarcinoma (ICCA) Market Drivers
19 Intrahepatic Cholangiocarcinoma (ICCA) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
23 DelveInsight Capabilities
25 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States